Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 9/20 | 1.00 |
| ▸ | KCNQ3 | O43525 | 7/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | SHMT2 | P34897 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flupirtine SCHEMBL3896230 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL15357226 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL25009 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505847 | 0.99 | KCNQ2 (0.98) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505535 | 0.99 | KCNQ2 (0.98) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL28262990 | 0.99 | KCNQ2 (0.98) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505446 | 0.98 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505680 | 0.98 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL1649863 | 0.98 | KCNQ2 (0.96) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 | |
| Flupirtine SCHEMBL505608 | 0.97 | KCNQ2 (0.94) | KCNQ2KCNQ3CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2025104452-A1 | COMPOUNDS FOR USE IN TREATMENT | MITORX THERAPEUTICS LTD (GB) | 2025-05-22 | — | — | WO | claimed |
| WO-2024015527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS, COMPANION DIAGNOSTICS AND METHODS FOR DOSAGING AND USING THEM | BAYESIAN BIOTECH, LLC (US) | 2024-01-18 | — | — | WO | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3380121-B1 | ACTRII ANTAGONIST FOR USE IN TREATING EYE DISORDERS | ACCELERON PHARMA INC (US) | 2023-12-20 | — | — | EP | claimed |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4714496-A2 | TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | OrfoNeuro ApS (DK) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077027-A1 | PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577282-B2 | Galectin-1/ galectin-3 chimeras and multivalent proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260053906-A1 | DNA ORIGAMI VACCINES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-02-26 | — | — | US | disclosed |
| US-11369593-B2 | Functionalized pyridine carbamates with enhanced neuroprotective activity | TEXAS TECH UNIVERSITY SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220175804-A1 | aPKC INHIBITORS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE OR DISORDER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-06-09 | — | — | US | disclosed |
| US-11324855-B2 | Cell-free combination, hydrogel-like material or hydrogel and use of same | TETEC TISSUE ENGINEERING TECHNOLOGIES AG (DE) | 2022-05-10 | — | — | US | disclosed |
| WO-2022076932-A1 | COMPOSITIONS AND METHODS OF TREATING A PI3K MEDIATED DISEASE | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106580-A1 | TARGETED CHONDROITINASE ABC FUSION PROTEINS AND COMPLEXES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220098258-A1 | GALECTIN-1/ GALECTIN-3 CHIMERAS AND MULTIVALENT PROTEINS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-20220054649-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577282-B2 | Galectin-1/ galectin-3 chimeras and multivalent proteins | LGALS1, LGALS3BP, LGALS3 | KCNQ2 4216/4885KCNQ3 3538/4885CYP1A2 4831/4885 |
| US-20260053906-A1 | DNA ORIGAMI VACCINES | CD47, RBM26, TP53 | KCNQ2 2568/4885KCNQ3 2364/4885CYP1A2 4867/4885 |
| US-11369593-B2 | Functionalized pyridine carbamates with enhanced neuroprotective activity | BDNF, CHRNA5, CHRNA4 | KCNQ2 783/4885KCNQ3 852/4885CYP1A2 1609/4885 |
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | RNMT, NSUN2, FBL | KCNQ2 4325/4885KCNQ3 4239/4885CYP1A2 4679/4885 |
| US-20220054649-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | KCNQ2 3807/4885KCNQ3 3774/4885CYP1A2 2004/4885 |
| US-20260077027-A1 | PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES | MICA, PDCD1LG2, TLR9 | KCNQ2 4279/4885KCNQ3 4094/4885CYP1A2 4882/4885 |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | FLNB, FLNA, DAGLB | KCNQ2 3598/4885KCNQ3 3240/4885CYP1A2 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.